For research use only
| Cat No. | ABC-TC0556 |
| Product Type | Human Esophageal Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Esophageal Squamous Cell Cancer |
| Product Code | KYSE 140; Kyse-140; Kyse140; KYSE-140 |
Human esophageal cancer cell line. Esophageal cancer, moderately differentiated squamous carcinoma
KYSE140 is a human esophageal squamous cell carcinoma (ESCC) line derived from a moderately differentiated tumor resected from the mid-thoracic esophagus of a 54-year-old male patient prior to any treatment. KYSE140 morphology is epithelial, and the cells grow as a cobblestone-like adherent monolayer, occasionally showing multilayered piling. Cytogenetic analysis reveals aneuploidy and complex chromosomal aberrations, consistent with ESCC profiles. KYSE140 harbors a TP53 mutation and exhibits oncogenic features such as high clonogenic capacity and stemness marker expression such as OCT4 and HIWI (PIWIL1). Additionally, it carries a NOTCH1 p.E450K mutation that confers chemoresistance. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | KYSE 140; Kyse-140; Kyse140; KYSE-140 |
| Species | Human |
| Cat.No | ABC-TC0556 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | Esophageal Squamous Cell Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Esophageal Cancer Cell Lines |
| Stock | Out of stock |
KYSE140 serves as a robust in vitro model to study ESCC pathogenesis, including tumorigenesis, chemoresistance mechanisms, and cancer stem cell behavior. It has been used to evaluate responses to conventional chemotherapeutics, targeted therapies, and photodynamic treatments. The presence of stem-like subpopulations makes it valuable for studies on tumor heterogeneity and self-renewal. Moreover, the NOTCH1 p.E450K mutation offers a valuable system for therapeutic screening aimed at overcoming drug resistance in ESCC.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
